Adaptive Biotechnologies Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ADPT research report →
Range $27 – $35
Price Chart
About the company
Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions.
- CEO
- Chad Robins
- IPO
- 2019
- Employees
- 624
- HQ
- Seattle, WA, US
Get TickerSpark's AI analysis on ADPT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $4.52B
- P/E
- -61.78
- Fwd P/E
- 267.81
- PEG
- -53.38
- P/S
- 15.17
- P/B
- 25.42
- EV/EBITDA
- -163.26
- Div Yield
- 0.00%
- Gross Margin
- 74.01%
- Op Margin
- -16.18%
- Net Margin
- -23.66%
- ROE
- -37.40%
- ROIC
- -8.13%
Latest fiscal year · YoY change
- Revenue
- $276.98M+54.8%
- Gross Profit
- $205.62M+92.4%
- Op Income
- $-57,123,000
- Net Income
- $-59,499,000+62.7%
- EPS
- $-0.39+63.9%
- OCF Growth
- +51.7%
- FCF Growth
- +50.5%
- 52W High
- $32.21
- 52W Low
- $12.00
- 50D MA
- $27.22
- 200D MA
- $20.29
- Beta
- 2.15
- RSI (14)
- 52
- Avg Volume
- 2.19M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Adaptive Biotechnologies delivered a breakout Q3 with company-wide profitability ahead of plan, strong MRD growth, and a raised full-year MRD outlook, while guidance and new myeloma-related developments strengthen the long-term case for clonoSEQ.· November 4, 2026
- Total company revenue was $83.9 million, up 39% year over year; MRD revenue was $72.6 million, up 28% year over year and 44% excluding prior-year milestone revenue.
- The company reached total-company adjusted EBITDA profitability at $14.3 million and generated $8 million of free cash flow, ending Q3 with about $386 million in cash.
- MRD clinical testing volume grew 46% year over year, with nearly 40,000 clonoSEQ tests delivered; DLBCL and multiple myeloma both contributed meaningfully.
- Management raised full-year 2026 MRD revenue guidance to $276 million-$286 million and kept full-year operating expenses near $350 million.
- New NCCN myeloma guidelines and a new definition of cure were highlighted as important catalysts for broader MRD use and future reimbursement expansion.
Total revenue was $83.9 million, up 39% year over year. MRD revenue was $72.6 million, up 28% year over year, or 44% excluding $6.5 million of milestone revenue recognized in the prior year period. Sequencing gross margin was 73% versus 66% a year ago, MRD sequencing gross margin was 74%, total company gross margin was 76%, and total company adjusted EBITDA was $14.3 million; GAAP net income was $2.8 million. The company ended the quarter with approximately $386 million in total cash and generated $8 million of free cash flow. For the full year, Adaptive raised MRD revenue guidance to $276 million-$286 million from $268 million-$278 million, continues to expect about $9 million of MRD milestone revenue for the year, expects full-year clinical volume growth of about 42%, and now expects full-year operating expenses of about $350 million.
Chad Robins framed Q3 as a breakthrough quarter, emphasizing that profitability arrived ahead of expectations while rapid MRD growth continued. He pointed to the combination of stronger clinical volume, pharma sequencing growth, and favorable guideline changes in multiple myeloma as reinforcing the long-term opportunity for clonoSEQ. His tone was notably confident and expansive, repeatedly stressing that the company is now seeing multiple catalysts converge across clinical care, reimbursement, and pharma development.
Kyle Piskel focused on the operating leverage in the business, noting sequencing gross margin improved to 73% from 66% a year ago and that MRD adjusted EBITDA rose to $15.1 million. He also highlighted that operating expenses were $84.4 million, up only 1% year over year, while the company generated positive adjusted EBITDA and free cash flow. On guidance, he raised full-year MRD revenue, said the company still expects $9 million of milestone revenue for the year, and lowered full-year operating expense expectations to about $350 million at the low end of the prior range.
Analysts focused on CMS rate-setting risk, 2027 growth drivers, DLBCL competition, the myeloma pharma backlog, and whether profitability changes capital deployment. Management said the company does not believe the PLA rate-setting process should materially affect the episodic Medicare framework, is working to correct erroneous data submitted to CMS, and remains confident in long-term pricing. On growth, executives said 2027 should be driven by a mix of guidelines, data, EMR integration, blood-based testing, and community expansion, while DLBCL remains a strong and underpenetrated market and myeloma pharma momentum is being helped by FDA draft guidance, the new cure definition, and more interventional/regulatory use. They also said profits will be reinvested into MRD, real-world data, AI/process automation, customer experience, and new platform applications.
The call showed multiple growth engines working together: clinical MRD volume, pharma sequencing, reimbursement progress, and guideline support. Management sounded increasingly confident that NCCN updates, the myeloma cure definition, and a potential maintenance bundle submission to MolDX can support both higher utilization and better pricing over time. Profitability and cash generation also give the company more room to reinvest while it continues to grow quickly.
Management acknowledged that ASP can face pressure from Medicare testing frequency and that timing around reimbursement changes is uncertain, even if they remain confident in the long-term path to higher ASP. Milestone revenue is still lumpy and hard to predict, and the company did not provide 2027 guidance. They also noted competitive noise in DLBCL and said CMS rate-setting data issues were being corrected, which adds some near-term uncertainty.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 97.0%
- Shares Outstanding
- 161.88M
- Float Shares
- 157.09M
of shares held by institutions
313 13F filers
Buy/sell ratio 0.15. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for ADPT, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Buy | Feb 14, 22 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Viking Global Investors LP | 29.99M | 0 |
| Blackrock, Inc. | 15.30M | ▲ 163.29K |
| Vanguard Group Inc | 11.28M | ▲ 6.98K |
| Vanguard Capital Management LLC | 6.44M | ▲ 32.46K |
| D. E. Shaw & Co., Inc. | 6.37M | ▲ 1.75M |
| Price T Rowe Associates Inc | 5.70M | ▲ 3.04M |
| Vanguard Portfolio Management LLC | 5.24M | ▼ 237.05K |
| Wellington Management Group Llp | 4.75M | ▼ 1.16M |
| Driehaus Capital Management LLC | 4.71M | ▲ 2.18M |
| Geode Capital Management, LLC | 3.72M | ▲ 78.68K |
| T. Rowe Price Investment Management, Inc. | 3.59M | ▲ 1.81M |
| State Street Corp | 3.56M | ▲ 98.90K |
Held by 317 ETFs
Biggest fund positions in ADPT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 12, 26 | RUBINSTEIN JULIE | other | 11,881 |
| Nov 13, 26 | RUBINSTEIN JULIE | other | 11,466 |
| Nov 11, 26 | RUBINSTEIN JULIE | sell | 4,983 |
| Nov 12, 26 | RUBINSTEIN JULIE | sell | 11,881 |
| Nov 11, 26 | RUBINSTEIN JULIE | sell | 6,898 |
| Nov 13, 26 | RUBINSTEIN JULIE | sell | 11,466 |
| Nov 11, 26 | RUBINSTEIN JULIE | other | 11,881 |
| Nov 12, 26 | RUBINSTEIN JULIE | other | 11,881 |
| Nov 13, 26 | RUBINSTEIN JULIE | other | 11,466 |
| Nov 11, 26 | BOBULSKY SUSAN | sell | 1,875 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ADPT coverage
Recent articles, reports, and earnings notes.
No research on ADPT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ADPT report →Adaptive Biotechnologies Highlights clonoSEQ's Central Role in Advancing MRD-Guided Care Across Hematology at ASH 2026
globenewswire.com · Nov 18
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
globenewswire.com · Nov 10
Adaptive Biotechnologies Corporation (ADPT) Hits Fresh High: Is There Still Room to Run?
zacks.com · Nov 10
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Has Average Target Price of $30.06
defenseworld.net · Nov 6
Adaptive Biotechnologies Corporation (ADPT) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 4
Adaptive Biotechnologies (ADPT) Q3 Earnings and Revenues Top Estimates
zacks.com · Nov 4
Adaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
zacks.com · Nov 4
Adaptive Biotechnologies Q3 Earnings Call Highlights
marketbeat.com · Nov 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.